The U.S. Food and Drug Administration approved the pill for weight loss earlier this month, intensifying Lilly's competition ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

The FDA has approved the second GLP-1 pill for overweight and obesity. How does it compare to the Wegovy oral pill?

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

By Sriparna Roy April 17 (Reuters) - Eli Lilly's newly launched weight-loss pill was prescribed 1,390 times in the U.S. in ...

Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is ...

Eli Lilly says it has the safety data it needs to shore up the recent speedy approval of its oral obesity therapy Foundayo, ...